Navigation Links
Centella Therapeutics Licenses Novel New Drug Designed to Enhance the Effectiveness of Cancer Treatment
Date:5/24/2011

PALO ALTO, Calif. and AUCKLAND, New Zealand, May 24, 2011 /PRNewswire/ -- Centella Therapeutics, Inc., a subsidiary of Varian Medical Systems, Inc. (NYSE: VAR), and Auckland UniServices Ltd. of Auckland, New Zealand, today announced that they have entered into a licensing agreement granting Centella exclusive rights to CEN-209, a novel investigational drug designed to enhance the effectiveness of radiotherapy and chemotherapy when treating solid tumors that are hypoxic—or oxygen-starved—and therefore resistant to standard forms of radiotherapy and chemotherapy.

CEN-209 is selectively activated in areas of low oxygen often found within solid tumors.  These areas develop within tumors due to their rapid growth, which impairs the blood vessels bringing nutrients and oxygen, resulting in hypoxia.  

"Hypoxic tumors are generally resistant to radiotherapy and to chemotherapy, and there is no effective treatment for such tumors today," says Thorsten Melcher, PhD, President of Centella Therapeutics.  "Hypoxia occurs in most types of solid tumors, but not necessarily in every patient with a given tumor type. For example, in lung cancer patients, roughly 50 percent of tumors have hypoxic regions.(1)  In the future, successful treatment of hypoxic tumors will likely require identifying affected patients and giving them a hypoxia-specific drug, like CEN-209, in addition to standard treatment."(2)

Radiotherapy works by damaging tumor cells' DNA, but only in well-oxygenated areas, whereas CEN-209 is designed to 'switch on' and damage the DNA only of hypoxic cells, leaving other cells alone," Melcher adds.  "Thus, the two treatment approaches have the potential to complement each other, and CEN-209 is specifically designed to be preferentially used in combination with radiotherapy."

Professor William Wilson and Associate Profes
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
3. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
4. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
5. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
6. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
7. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
8. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
9. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
10. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
11. Cell Therapeutics, Inc. (CTI) Sponsors Panel Discussion on Women and Lung Cancer on Capitol Hill
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 Patient engagement has become ... organizations are turning to an assortment of marketing ... part of this evolving approach to patient engagement, ... and engage patients throughout their experiences with a ... By mapping the patient journey and employing a ...
(Date:7/11/2014)... , July 11, 2014 Research ... "Global Hypodermic Needles Market 2014-2018" report to their ... A hypodermic needle is a hollow needle commonly ... body or or to extract fluids from it. A ... or to inject substances that cannot be ingested. Hypodermic ...
(Date:7/11/2014)... -- Research and Markets ( http://www.researchandmarkets.com/research/tjlw9k/immunoprotein ) has ... Testing Market - Forecasts to 2019: Expected to ... is expected to be valued at USD 4,943.0 ... http://photos.prnewswire.com/prnh/20130307/600769 The ... according to immunoprotein types which include immunoglobulins, complement ...
Breaking Medicine Technology:New Study Uses Six-Step Patient Journey as Framework for Consumer-Focused Marketing Opportunities 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 2Global Hypodermic Needles Market 2014-2018: Key Vendors are Becton, Dickinson and Co, Covidien, Retractable Technologies and Terumo Corp. 3Immunoprotein Diagnostic Testing Market - Forecasts to 2019: Expected to grow at the highest CAGR of 6% and is expected to be valued at USD 4,943.0 million 2
... and ABBOTT PARK, Ill., June 24, 2011 New ... The New England Journal of Medicine show ... and type 2 diabetes receiving bardoxolone methyl for 52 ... the treatment period, as measured by estimated glomerular filtration ...
... 24, 2011 , Comprehensive , F ... ow , A vailable in Canada, U.K. ... world-leading provider of scientific, technical and,medical information products and services, ... of the United States, enabling,institutions to identify international funding opportunities. ...
Cached Medicine Technology:New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 2New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 3New Phase 2 Data Published in New England Journal of Medicine Show Bardoxolone Methyl Sustained Improvement in Measure of Kidney Function (eGFR) Over 52 Weeks in Patients With Moderate to Severe Chronic Kidney Disease and Type 2 Diabetes 4Elsevier's SciVal Funding Expands Globally 2Elsevier's SciVal Funding Expands Globally 3
(Date:7/11/2014)... 11, 2014 According to a new ... Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, Wi-Fi, NFC, ... Automotive & Transportation, Agriculture) & Geography - Global Trends ... Internet of Things market was worth $1029.5 Billion in ... 2020, at an estimated CAGR of 4.08% from 2014 ...
(Date:7/11/2014)... Biostimulants are widely applied in turf and ornamentals. ... also help turf and ornamentals in absorption of water, ... and flowers appear healthy and strong as a result ... the last few years. The most dominating region in ... around 40% share in 2013, and is estimated to ...
(Date:7/11/2014)... July 11, 2014 As reported by ... FiercePharma (Weintraub 7/11/14), a significant number of severe adverse ... abdominal issues and even death from the highly-promoted and ... to the Times report , a regulatory filing ... reported by patients was almost 14% of prescriptions, up ...
(Date:7/11/2014)... and overweight firefighters are not receiving weight management ... new research from The University of Texas Health ... state that health care professionals (HCPs) should advise ... weight. Firefighters have high rates of obesity, and ... deaths in firefighters. This study assessed the association ...
(Date:7/11/2014)... The Corn Farming industry experienced ... the heels of fresh biofuel demand. The Federal Renewable ... larger share of their farmland to cultivating high-value corn ... the mixing of 5.0% renewable content in gasoline across ... States created a key export market for Canadian corn, ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:Biostimulants Market in Turf and Ornamentals is Expected to Reach $ 3.8 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:Acthar’s Deadly Adverse Events Revealed 2Health News:Acthar’s Deadly Adverse Events Revealed 3Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 2Health News:Corn Farming in Canada Industry Market Research Report Now Available From IBISWorld 3
... County residents will have the opportunity to witness a special, ... traditional lighting of the Saugatuck River Bridge at dusk. Those ... the door, will enjoy cuisine and drink from some of ... chance to participate in a silent auction that includes items ...
... VIEW, Calif., July 7 ... has closed its acquisition of the Managed Security Services ... VeriSign is the trusted provider of Internet infrastructure services ... strengthens its leadership position as a global, pure-play security ...
... , MORTON GROVE, Ill., July 7 Lifeway Foods, Inc. (Nasdaq: ... a provider of other natural and organic dairy products, invites you ... throws out the first pitch before the Chicago Cubs take on ... , At this official "Lifeway Day with the Cubs," the local ...
... July 7 /PRNewswire-Asia-FirstCall/ -- Biostar,Pharmaceuticals, Inc. (OTC Bulletin Board: ... and supplier of pharmaceutical,products and medical nutrients addressing a ... has commenced the full implementation of the,new rural cooperative ... Since the beginning of April, Biostar has deployed ...
... Web reports by states and municipalities , TUESDAY, July ... the United States get mixed marks for their use of ... outbreak, a new study shows. , After the U.S. government ... state health departments posted some information about the H1N1 outbreak ...
... the director of Developmental Care and Follow-up at Texas Children,s ... Medicine , has been appointed chair of the American Academy ... assumed the role on July 1st and will oversee the ... succeed Ann Stark, M.D., FAAP, chief of Neonatology at Texas ...
Cached Medicine News:Health News:Al's Angels' 'Angels in July' Saugatuck River Bridge Lighting to Benefit Children in Need 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 2Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 3Health News:SecureWorks Closes Acquisition of VeriSign's Managed Security Services Business 4Health News:Giant Bugs Invade Wrigley Field 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 2Health News:Biostar Pharmaceuticals, Inc. Commences the Full Implementation of New Rural Cooperative Supply Network Plan 3Health News:Mixed Marks for Swine Flu Updates 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 2Health News:The American Academy of Pediatrics Names Lu-Ann Papile, M.D., FAAP, as Chair of the Fetus and Newborn Committee 3
Zebras H 2824-Z Healthcare Starter Kit includes everything you need to start printing wristbands today: the H 2824-Z direct thermal printer, a pre-installed Media Adapter Guide, and a roll of adult-s...
... Hugs® system software presents only ... a familiar Windows-based PC environment. Up ... connected at other locations throughout the ... network (LAN). Nurses, security personnel and ...
... is designed to protect a wandering resident ... lost or injured. Such residents typically have ... have suffered a head injury., At-risk residents ... wrist or ankle, and points of exit ...
... be programmed to send hospital-defined ... device needs servicing, preventive maintenance ... patient or staff member needs ... ID-tag includes the current location ...
Medicine Products: